Evaluation of Repeat Administration of Purified Poloxamer 188

Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.

Inclusion Criteria:

• Completed participation in study MST-188-01 (EPIC study)
• Subject age 4 through 65 years
• Subject is experiencing acute pain typical of VOC and requires treatment with parenteral opioid analgesia
• Subject requires hospitalization

Exclusion Criteria:

• Subject has acute chest syndrome
• Subject's laboratory results indicate inadequate organ function
• Subject is pregnant or nursing an infant
• Subject had a painful crisis requiring hospitalization within the preceding 14 days
• Subject has been transfused within the past 14 days
• Subject has complications related to SCD